Dataset Information

Alkylation base damage is converted into repairable double-strand breaks and complex intermediates in G2 cells lacking AP endonuclease.

ABSTRACT: DNA double-strand breaks (DSBs) are potent sources of genome instability. While there is considerable genetic and molecular information about the disposition of direct DSBs and breaks that arise during replication, relatively little is known about DSBs derived during processing of single-strand lesions, especially for the case of single-strand breaks (SSBs) with 3'-blocked termini generated in vivo. Using our recently developed assay for detecting end-processing at random DSBs in budding yeast, we show that single-strand lesions produced by the alkylating agent methyl methanesulfonate (MMS) can generate DSBs in G2-arrested cells, i.e., S-phase independent. These derived DSBs were observed in apn1/2 endonuclease mutants and resulted from aborted base excision repair leading to 3' blocked single-strand breaks following the creation of abasic (AP) sites. DSB formation was reduced by additional mutations that affect processing of AP sites including ntg1, ntg2, and, unexpectedly, ogg1, or by a lack of AP sites due to deletion of the MAG1 glycosylase gene. Similar to direct DSBs, the derived DSBs were subject to MRX (Mre11, Rad50, Xrs2)-determined resection and relied upon the recombinational repair genes RAD51, RAD52, as well as on the MCD1 cohesin gene, for repair. In addition, we identified a novel DNA intermediate, detected as slow-moving chromosomal DNA (SMD) in pulsed field electrophoresis gels shortly after MMS exposure in apn1/2 cells. The SMD requires nicked AP sites, but is independent of resection/recombination processes, suggesting that it is a novel structure generated during processing of 3'-blocked SSBs. Collectively, this study provides new insights into the potential consequences of alkylation base damage in vivo, including creation of novel structures as well as generation and repair of DSBs in nonreplicating cells.

SUBMITTER: Ma W

PROVIDER: S-EPMC3084215 | biostudies-literature | 2011 Apr

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Alkylation base damage is converted into repairable double-strand breaks and complex intermediates in G2 cells lacking AP endonuclease.

Ma Wenjian W Westmoreland Jim W JW Gordenin Dmitry A DA Resnick Mike A MA

PLoS genetics 20110428 4

DNA double-strand breaks (DSBs) are potent sources of genome instability. While there is considerable genetic and molecular information about the disposition of direct DSBs and breaks that arise during replication, relatively little is known about DSBs derived during processing of single-strand lesions, especially for the case of single-strand breaks (SSBs) with 3'-blocked termini generated in vivo. Using our recently developed assay for detecting end-processing at random DSBs in budding yeast, ...[more]

PMID: 21552545

Similar Datasets

Project description:Abstract Glioblastoma (GBM) is the most common brain cancer. Systemic therapy with temozolomide or nitrosoureas is often ineffective due to the activity of the DNA repair enzyme O6-methylguanine-DNA-methyltransferase (MGMT). Patients with recurrent GBM have limited treatment options and very poor prognosis. Dianhydrogalactitol (VAL-083) is a first-in-class bifunctional alkylating agent that rapidly induces interstrand DNA cross-links targeting N7 of guanine leading to cell cycle arrest and apoptosis due to DNA double-strand breaks. VAL-083 readily crosses the blood-brain barrier, accumulates in brain tumor tissue and has shown activity in prior NCI-sponsored clinical trials against CNS tumors, including GBM and medulloblastoma. We have previously shown that VAL-083´s cytotoxic activity is independent of MGMT in contrast to temozolomide and nitrosoureas. We have also demonstrated VAL-083 is active against GBM cancer stem cells (CSCs) and acts as a radiosensitizer in GBM CSCs, in vitro. We have also previously shown that VAL-083 circumvents cisplatin-resistance and is less dependent on p53 activity than cisplatin suggesting a distinct mechanism of action for VAL-083. We recently completed enrollment of a Phase I/II clinical trial in the United States for recurrent GBM in patients who have failed temozolomide and bevacizumab (clinicaltrials.gov identifier: NCT01478178). Separate clinical trials are planned in GBM patients with high expression of MGMT both in recurrent bevacizumab-naive GBM patients (clinicaltrials.gov identifier: NCT02717962) and in newly diagnosed GBM patients utilizing MGMT promoter methylation as a validated biomarker for patient selection. Here we report new insights into VAL-083 mechanism of action by showing that VAL-083 rapidly induces interstrand DNA cross-links leading to irreversible S/G2 cell-cycle arrest and cell death caused by replication-dependent DNA damage. VAL-083 pulse-treatment leads to persistent phosphorylation of DNA double-strand break (DSB) sensors ATM, single-strand DNA-binding Replication Protein A (RPA32), and histone variant H2A.X. After 10 months in culture, following a standard protocol for inducing chemo-resistance, cancer cells remained sensitive to VAL-083 at low M concentrations. Taken together, these results support a unique molecular mechanism for VAL-083 that differs from both temozolomide, nitrosoureas or cisplatin. Our data further suggest that the mechanism of VAL-083 is impervious to important DNA-repair strategies employed by cancer cells to escape effects of alkylating agents commonly used in the treatment of GBM and that efficient resistance mechanisms against VAL-083 treatment are not easily acquired by cancer cells.

Dataset Information

Alkylation base damage is converted into repairable double-strand breaks and complex intermediates in G2 cells lacking AP endonuclease.

Publications

Alkylation base damage is converted into repairable double-strand breaks and complex intermediates in G2 cells lacking AP endonuclease.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets